| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot knockout validation; human; fig 8
- chromatin immunoprecipitation; human; fig 5
- immunocytochemistry; human; fig 2
| Li Y, Long X, Huang L, Yang M, Yuan Y, Wang Y, et al. Epstein-Barr Virus BZLF1-Mediated Downregulation of Proinflammatory Factors Is Essential for Optimal Lytic Viral Replication. J Virol. 2016;90:887-903 pubmed publisher |
- western blot; human; fig 6h
| Biswas A, Zhou D, Fiches G, Wu Z, Liu X, Ma Q, et al. Inhibition of polo-like kinase 1 (PLK1) facilitates reactivation of gamma-herpesviruses and their elimination. PLoS Pathog. 2021;17:e1009764 pubmed publisher |
- western blot; human; 1:500; loading ...; fig 1j
| Full F, van Gent M, Sparrer K, Chiang C, Zurenski M, Scherer M, et al. Centrosomal protein TRIM43 restricts herpesvirus infection by regulating nuclear lamina integrity. Nat Microbiol. 2019;4:164-176 pubmed publisher |
- western blot; human; loading ...; fig 2c
| Wang H, Bu L, Wang C, Zhang Y, Zhou H, Zhang X, et al. The Hsp70 inhibitor 2-phenylethynesulfonamide inhibits replication and carcinogenicity of Epstein-Barr virus by inhibiting the molecular chaperone function of Hsp70. Cell Death Dis. 2018;9:734 pubmed publisher |
- immunocytochemistry; human; 1:100; loading ...; fig 2
- western blot; human; 1:250; loading ...; fig 8a
| Kraus R, Yu X, Cordes B, Sathiamoorthi S, Iempridee T, Nawandar D, et al. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter. PLoS Pathog. 2017;13:e1006404 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200; fig 2
- western blot; human; 1:250; fig 4
| Nawandar D, Wang A, Makielski K, Lee D, Ma S, Barlow E, et al. Differentiation-Dependent KLF4 Expression Promotes Lytic Epstein-Barr Virus Infection in Epithelial Cells. PLoS Pathog. 2015;11:e1005195 pubmed publisher |
- immunocytochemistry; human; 1:600
- western blot; human; 1:5000
| Mansouri S, Pan Q, Blencowe B, Claycomb J, Frappier L. Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer. J Virol. 2014;88:11166-77 pubmed publisher |
| Xu X, Zhu N, Zheng J, Peng Y, Zeng M, Deng K, et al. EBV abortive lytic cycle promotes nasopharyngeal carcinoma progression through recruiting monocytes and regulating their directed differentiation. PLoS Pathog. 2024;20:e1011934 pubmed publisher |
| de la Cruz Herrera C, Tatham M, Siddiqi U, Shire K, Marcon E, Greenblatt J, et al. Changes in SUMO-modified proteins in Epstein-Barr virus infection identifies reciprocal regulation of TRIM24/28/33 complexes and the lytic switch BZLF1. PLoS Pathog. 2023;19:e1011477 pubmed publisher |
| Van Sciver N, Ohashi M, Nawandar D, Pauly N, Lee D, Makielski K, et al. ΔNp63α promotes Epstein-Barr virus latency in undifferentiated epithelial cells. PLoS Pathog. 2021;17:e1010045 pubmed publisher |
| Chen Y, Fachko D, Ivanov N, Skalsky R. B Cell Receptor-Responsive miR-141 Enhances Epstein-Barr Virus Lytic Cycle via FOXO3 Inhibition. mSphere. 2021;6: pubmed publisher |
| Chakravorty S, Yan B, Wang C, Wang L, Quaid J, Lin C, et al. Integrated Pan-Cancer Map of EBV-Associated Neoplasms Reveals Functional Host-Virus Interactions. Cancer Res. 2019;79:6010-6023 pubmed publisher |
| CHENG A, Yockteng Melgar J, Jarvis M, Malik Soni N, Borozan I, Carpenter M, et al. Epstein-Barr virus BORF2 inhibits cellular APOBEC3B to preserve viral genome integrity. Nat Microbiol. 2019;4:78-88 pubmed publisher |
| Guidry J, Myers J, Bienkowska Haba M, Songock W, Ma X, Shi M, et al. Inhibition of Epstein-Barr Virus Replication in Human Papillomavirus-Immortalized Keratinocytes. J Virol. 2019;93: pubmed publisher |
| Bristol J, Djavadian R, Albright E, Coleman C, Ohashi M, Hayes M, et al. A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection. PLoS Pathog. 2018;14:e1007179 pubmed publisher |
| Zhang H, Tian J, Qi X, Xiang T, He G, Zhang H, et al. Epstein-Barr virus activates F-box protein FBXO2 to limit viral infectivity by targeting glycoprotein B for degradation. PLoS Pathog. 2018;14:e1007208 pubmed publisher |
| Frisan T, Nagy N, Chioureas D, Terol M, Grasso F, Masucci M. A bacterial genotoxin causes virus reactivation and genomic instability in Epstein-Barr virus infected epithelial cells pointing to a role of co-infection in viral oncogenesis. Int J Cancer. 2019;144:98-109 pubmed publisher |
| Nawandar D, Ohashi M, Djavadian R, Barlow E, Makielski K, Ali A, et al. Differentiation-Dependent LMP1 Expression Is Required for Efficient Lytic Epstein-Barr Virus Reactivation in Epithelial Cells. J Virol. 2017;91: pubmed publisher |
| Zhang W, Han D, Wan P, Pan P, Cao Y, Liu Y, et al. ERK/c-Jun Recruits Tet1 to Induce Zta Expression and Epstein-Barr Virus Reactivation through DNA Demethylation. Sci Rep. 2016;6:34543 pubmed publisher |
| Djavadian R, Chiu Y, Johannsen E. An Epstein-Barr Virus-Encoded Protein Complex Requires an Origin of Lytic Replication In Cis to Mediate Late Gene Transcription. PLoS Pathog. 2016;12:e1005718 pubmed publisher |
| Ma S, Xu X, Jones R, Delecluse H, Zumwalde N, Sharma A, et al. PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. PLoS Pathog. 2016;12:e1005642 pubmed publisher |
| Wille C, Nawandar D, Henning A, Ma S, Oetting K, Lee D, et al. 5-hydroxymethylation of the EBV genome regulates the latent to lytic switch. Proc Natl Acad Sci U S A. 2015;112:E7257-65 pubmed publisher |
| Liu X, Cohen J. Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase. J Virol. 2016;90:1129-38 pubmed publisher |
| Quinn L, Zuo J, Abbott R, Shannon Lowe C, Tierney R, Hislop A, et al. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle. PLoS Pathog. 2014;10:e1004322 pubmed publisher |
| Sun X, Bristol J, Iwahori S, Hagemeier S, Meng Q, Barlow E, et al. Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells. J Virol. 2013;87:10126-38 pubmed publisher |
| Mansouri S, Wang S, Frappier L. A role for the nucleosome assembly proteins TAF-I? and NAP1 in the activation of BZLF1 expression and Epstein-Barr virus reactivation. PLoS ONE. 2013;8:e63802 pubmed publisher |
| Raver R, Panfil A, Hagemeier S, Kenney S. The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1. J Virol. 2013;87:8053-63 pubmed publisher |
| Hoebe E, Wille C, Hopmans E, Robinson A, Middeldorp J, Kenney S, et al. Epstein-Barr virus transcription activator R upregulates BARF1 expression by direct binding to its promoter, independent of methylation. J Virol. 2012;86:11322-32 pubmed |
| Sivachandran N, Wang X, Frappier L. Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection. J Virol. 2012;86:6146-58 pubmed publisher |
| Robinson A, Kwek S, Kenney S. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1. PLoS Pathog. 2012;8:e1002516 pubmed publisher |
| Robinson A, Kwek S, Hagemeier S, Wille C, Kenney S. Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency. J Virol. 2011;85:8940-53 pubmed publisher |
| Yu X, McCarthy P, Lim H, Iempridee T, Kraus R, Gorlen D, et al. The ZIIR element of the Epstein-Barr virus BZLF1 promoter plays a central role in establishment and maintenance of viral latency. J Virol. 2011;85:5081-90 pubmed publisher |
| Bristol J, Robinson A, Barlow E, Kenney S. The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins. J Virol. 2010;84:12362-74 pubmed publisher |
| Ellis Connell A, Iempridee T, Xu I, Mertz J. Cellular microRNAs 200b and 429 regulate the Epstein-Barr virus switch between latency and lytic replication. J Virol. 2010;84:10329-43 pubmed publisher |
| Yang E, Webster Marketon J, Chen M, Lo K, Kim S, Glaser R. Glucocorticoids activate Epstein Barr virus lytic replication through the upregulation of immediate early BZLF1 gene expression. Brain Behav Immun. 2010;24:1089-96 pubmed publisher |
| Ellis A, Wang Z, Yu X, Mertz J. Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner. J Virol. 2010;84:6139-52 pubmed publisher |
| Hagemeier S, Dickerson S, Meng Q, Yu X, Mertz J, Kenney S. Sumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase. J Virol. 2010;84:4383-94 pubmed publisher |
| Angelova A, Aprahamian M, Balboni G, Delecluse H, Feederle R, Kiprianova I, et al. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies. Mol Ther. 2009;17:1164-72 pubmed publisher |
| Dickerson S, Xing Y, Robinson A, Seaman W, Gruffat H, Kenney S. Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promoters. PLoS Pathog. 2009;5:e1000356 pubmed publisher |
| Li D, Qian L, Chen C, Shi M, Yu M, Hu M, et al. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation. J Immunol. 2009;182:1799-809 pubmed publisher |
| Jiang Y, Xu D, Zhao Y, Zhang L. Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma. PLoS ONE. 2008;3:e1569 pubmed publisher |
